BN
Balu N. Balasubramanian
Interim Chief Technology OfficerDr. Balu N. Balasubramanian PhD, ACSF, serves as Interim Chief Technology Officer of Pyxis Oncology, Inc. since 2022. He served as Managing Director of Bristol-Myers Squibb-Biocon Research Center. Dr. Balasubramanian leads the Pharma Innovation Sourcing Center. Dr. Balasubramanian has over 25 years of scientific and management experience in drug discovery and early clinical development. He serves as Board Observer at Outlook Therapeutics, Inc. (formerly known as Oncobiologics, Inc.) He served as a Member of scientific Advisory Board at Cadila Healthcare Limited since December 15, 2011.
Positions
- Company NamePyxis Oncology, Inc.Stock CodePYXSPositionInterim Chief Technology OfficerColleagues
- TCThomas CivikCEO & Chairman
- JWJitendra WadhaneChief Accounting Officer, Senior VP of Finance, Corporate Controller & Principal Financial Officer
- DRDonna RegaladoHead of Human Resources
- CTCharles T. GombarSenior Vice President of Portfolio & Program Management
- JLJohn L. FlavinLead Independent Director
- DSDarren S. ClineIndependent Director
- MRMorris RosenbergChairperson of Technical Advisory Board
- COChristopher O’DonnellMember of Technical Advisory Board
